logo
Share SHARE
FONT-SIZE Plus   Neg

Endo Buys US Patent For Oxymorphone From Johnson Matthey - Quick Facts

Endo Pharmaceuticals Holdings (ENDP) said it has acquired U.S. patent for oxymorphone hydrochloride, the key API in all formulations of OPANA, from Johnson Matthey plc (JMAT.L).

By acquiring Johnson Matthey's patent to the oxymorphone ingredient, which will be listed in the U.S. Food and Drug Administration's Orange Book, Endo will enjoy additional patent protection for its OPANA franchise, now through 2029.

"This patent not only covers our newly designed to be crush resistant OPANA® ER, it covers all products that include oxymorphone that are manufactured in accordance with current FDA specifications," said Julie McHugh, chief operating officer of Endo.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
H&R Block reported a smaller loss for the first quarter, driven by a four percent increase in revenues, partly offset by foreign currency fluctuations. The company announced a $3.5 billion stock buyback, and its shares gained 7% in after-hours trade... About nine-tenths of the world's sea birds are likely to have consumed pieces of plastic which continue to remain in their guts, a study shows. Automakers reported some mixed U.S. sales for August, marked by fewer working days and a delayed Labor Day, even as the month was largely bullish, spurred by lower interest rates, cheaper gas, and some strong employment data that buoyed consumer confidence.
comments powered by Disqus
RELATED NEWS
Trade ENDP now with 
Follow RTT